The scientific journal Molecular Cell, published on June 5, 2025, features a high-impact review article titled “Emerging mechanisms underlying formaldehyde toxicity and response“.
The study, authored by Marta Valverde-Santiago and Lucas B. Pontel—researchers at the Centro Nacional de Investigaciones Oncológicas (CNIO) and the German Cancer Research Center (DKFZ), respectively—offers an in-depth overview of the toxic effects of formaldehyde and the biological pathways activated in response to this compound.
Formaldehyde, classified as a Group 1 human carcinogen by the International Agency for Research on Cancer (IARC), is both an environmental pollutant and an endogenous metabolite. It is produced naturally in cells through various metabolic pathways and rapidly reacts with electron-rich biomolecules such as nucleic acids and proteins. This interaction can lead to severe damage at the molecular level, including DNA–protein and RNA–protein cross-links, disruption of cellular redox balance, and altered differentiation processes.
The authors highlight recent advances in our understanding of the molecular mechanisms that repair these cross-links and discuss how these pathways are linked to inherited disorders such as Fanconi anemia, AMeD, Ruijs-Aalfs, and Cockayne syndromes. In individuals affected by these conditions, cellular systems are less capable of neutralizing formaldehyde, making them more vulnerable to its genotoxic effects, with potentially serious implications for hematopoietic stem cells and other critical cell populations.
The review also draws attention to how endogenous formaldehyde accumulation may drive mutational signatures similar to those observed in certain cancers. Furthermore, it points out that tissue samples preserved with formaldehyde often exhibit sequence artifacts, complicating the interpretation of genetic analyses. These findings are particularly relevant in clinical and research settings where tissue integrity and genetic fidelity are crucial.
In light of this growing body of evidence, the need to phase out formaldehyde in pathology and molecular biology laboratories is becoming increasingly urgent.
Safer alternatives like GAF® (Glyoxal Acid-Free) now make it possible to achieve high-quality tissue fixation without the health hazards associated with reactive aldehydes. Addax Biosciences has long been committed to developing and promoting such solutions, enabling scientists and clinicians to work in safer environments while preserving the diagnostic and research value of biological samples.
The publication of this article in Molecular Cell provides further scientific validation for the transition toward non-toxic fixatives. Replacing formaldehyde is no longer simply a matter of precaution—it is a scientifically backed necessity for anyone involved in histopathology, genomics, or translational research. At Addax Biosciences, we firmly believe that true innovation begins with protecting both human health and scientific integrity.